Anifrolumab
- Generic Name
- Anifrolumab
- Brand Names
- Saphnelo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1326232-46-5
- Unique Ingredient Identifier
- 38RL9AE51Q
- Background
Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus. The standard therapy for systemic lupus erythematosus consists of antimalarials like hydroxychloroquine, glucocorticoids like dexamethasone, and disease modifying ant...
- Indication
Anifrolumab is indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.
- Associated Conditions
- Moderate Systemic Lupus Erythematosus (SLE), Severe Systemic Lupus Erythematosus (SLE)
- Associated Therapies
- -
Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 277
- Registration Number
- NCT04931563
- Locations
- 🇹🇭
Research Site, Bangkok, Thailand
Anifrolumab Early Access Program
- Conditions
- First Posted Date
- 2021-02-11
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- AstraZeneca
- Registration Number
- NCT04750057
Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE
- Conditions
- Interventions
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2023-03-22
- Lead Sponsor
- Oklahoma Medical Research Foundation
- Target Recruit Count
- 20
- Registration Number
- NCT04726553
- Locations
- 🇺🇸
Yale University Medical Center, New Haven, Connecticut, United States
🇺🇸New York University Medical Center, New York, New York, United States
🇺🇸Columbia Unversity Medical Center, New York, New York, United States
A Study to Target the Type I IFN Receptor by Administrating Anifrolumab in RA Patients With a High IFN Signature (TarIFNiRA)
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Josef Smolen, Univ. Prof. Dr.
- Target Recruit Count
- 24
- Registration Number
- NCT03435601
- Locations
- 🇦🇹
Medizinische Universität Wien, Innere Medizin III, Abteilung für Rheumatologie, Wien, Austria
🇦🇹Medizinische Universität Graz, Klinische Abteilung für Rheumatologie und Immunologie, Graz, Austria
🇦🇹Krankenhaus Hietzing, 2. Medizinische Abteilung, Wien, Austria
A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT02962960
- Locations
- 🇵🇱
Research Site, Warszawa, Poland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.